Airway and cough responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure

T P Chua, U G Laloo, M Y Worsdell, S Kharitonov, K F Chung, A J S Coats

Abstract

Objective—To investigate the airway and cough responsiveness in non-smoking patients with stable chronic heart failure. Cough and wheeze, features associated with hyper-responsive airways, are not uncommon especially in decompensated chronic heart failure. Bronchial hyper-responsiveness has previously been demonstrated in chronic heart failure but this may have been confounded by smoking and acute decompensation.

Design—Case-control study.

Setting—Tertiary specialist hospital.

Patients and interventions—Airway responsiveness to methacholine (a direct stimulant of smooth muscle in the airways), sodium metabisulphite (a putative stimulant of airway sensory nerves), and exercise was examined in 10 non-smoking patients with stable chronic heart failure (age 56·5 (3·2) (SEM) years; 7 men; median (interquartile) left ventricular ejection fraction 20·8 (2·9)%; radiographic cardiothoracic ratio 0·56 (0·02)). Exhaled nitric oxide, a product of the action of pro-inflammatory cytokines, was also measured to assess the contribution of local inflammation to airway responsiveness.

The cough responses to low-concentration chloride solutions and to capsaicin were studied. Because all patients were receiving angiotensin-converting enzyme inhibitors, which may influence airway responsiveness and cough, 8 asymptomatic non-smoking controls taking angiotensin-converting enzyme inhibitors for essential hypertension were also studied (age 54·3 (2·8) years; 6 men; radiographic cardiothoracic ratio 0·46 (0·01)).

Results—The mean provocative concentration that induced a 20% decrease in forced expiratory volume in 1 second (FEV₁) was 67·6 v 79·8 mg/ml (P = 0·71) for methacholine and 276·7 v 290·4 mg/ml (P = 0·79) for sodium metabisulphite in chronic heart failure patients and controls respectively. The change in FEV₁ after maximal cardiopulmonary exercise testing was +1·44% in patients and +2·53% in controls (P = 0·47), indicating that there was no exercise-induced bronchospasm in either group (peak oxygen consumption was 16·9 (1·3) v 26·5 (2·3) ml/kg/min respectively, P < 0·01).

Exhaled nitric oxide concentration was not increased in chronic heart failure (12·3 (1·7) v 16·2 (3·3) ppb, P = 0·32). The median cough counts after nebulised 0 mM and 37·5 mM chloride solutions were 2·5 v 1·0 (P = 0·6) and 5·8 v 5·0 (P = 0·5) respectively and the capsaicin concentration causing two or more coughs was 13·5 v 6·5 μM (P = 0·5).

Conclusion—Airway hyper-responsiveness is not a predominant feature in non-smoking patients with stable chronic heart failure treated with, and tolerant to, angiotensin-converting enzyme inhibitors. It is unlikely to contribute to the exertional dyspnoea seen in these patients.

(Heart 1996:76:144–149)

Keywords: airway responsiveness; cough response; exhaled nitric oxide; chronic heart failure

Exertional dyspnoea is a limiting symptom in chronic heart failure. Cough and wheeze, features associated with hyper-responsive airways, are not uncommon especially in decompensated chronic heart failure.

Classically, non-specific bronchial hyper-responsiveness is seen in bronchial asthma and is assessed using aerosols of histamine and acetylcholine or its analogue, methacholine, with monitoring of the bronchoconstrictor response in terms of the reduction in forced expiratory volume. Several studies have described bronchial hyper-responsiveness in chronic heart failure, but this is not a unambiguous finding. The number of patients in these studies is small and the findings are often confounded by acute decompensation of chronic heart failure, current smoking, or stopping treatment (including diuretics) before assessment. Pison et al found that bronchial hyper-responsiveness in patients with decompensated chronic heart failure did not improve 5–15 days after increased diuretic treatment, confirming that a recent history of acute pulmonary oedema may affect bronchial responsiveness. Cabanes et al showed that inhalation of the vasocostricctor methoxamine, an alpha-receptor agonist, lessened the methacholine-induced bronchial hyper-responsiveness and suggested that bronchial hyper-responsiveness was in part due to the vaso dilatory effect of methacholine causing further oedema and narrowing of the airways even without an increase in smooth muscle tone. Some investigators have postulated that, in addition to airway oedema, a neural reflex mediates bronchial hyper-responsiveness.
This may be secondary to the stimulation of pulmonary stretch (J) receptors by raised pulmonary venous pressure, although a significant correlation between pulmonary haemodynamics and bronchial hyper-responsiveness could not be demonstrated. Local airway inflammation has also been suggested as a cause of bronchial hyper-responsiveness but the presence of inflammatory cells and mediators has yet to be explored.1

To investigate the role of bronchial hyper-responsiveness in the generation of dyspnoea in chronic heart failure and to help in the understanding of the pathophysiology of this condition, we investigated several aspects of airway responsiveness in patients with chronic heart failure who were stable and non-smoking. This avoids the possible confounding factors discussed above. Specifically, we examined whether the the airways were hyper-responsive to: (a) methacholine, a direct airway smooth muscle stimulant; (b) sodium metabisulphite, a putative stimulant of airway sensory nerves; and (c) exercise. In addition, the cough responses to low-concentration chloride solutions and capsaicin were studied. We also investigated whether exhaled nitric oxide concentrations were increased in these patients as they are in patients with inflammatory airway disease, such as asthma, due to the action of proinflammatory cytokines.9 10

Patients and methods
Ten patients (age range 40–68 years, mean 56-5 (3-2) (SEM) years; seven men and three women) with stable symptomatic chronic heart failure and no history of acute decompensation within six months of the study were recruited. Patients were non-smokers or had stopped smoking for at least five years before the study. Patients with a history of asthma, chronic obstructive airways disease, or other airway disease were excluded. All had a radionuclide left ventricular ejection fraction of less than 35% (range 9–33%, mean 20-8 (2-9)% and were receiving stable treatment with both diuretic (mean daily dose of frusmide 80 mg, range 40–200 mg) and angiotensin-converting enzyme inhibitor medication. None was limited by angina although three patients were taking calcium antagonists and four nitrates. All patients had cardiac catheterisation before the study (eight with right and left heart studies, two with left heart only). Standard lung function tests and chest radiographs (mean radiographic cardiothoracic ratio 0·56 (0·02)) were also performed in these patients. Because all patients were receiving angiotensin-converting enzyme inhibitors, which may influence airway responsiveness and cough, eight asymptomatic non-smoking controls taking angiotensin-converting enzyme inhibitors for essential hypertension were also studied (age range 42–65 years, mean 54-3 (2-8) years; six men and two women; radiographic cardiothoracic ratio 0·46 (0·01)). None of the subjects was troubled by cough during treatment with angiotensin-converting enzyme inhibitors. Table 1 shows the clinical characteristics of the patients with chronic heart failure. This study was approved by the local ethics committee and all subjects gave written informed consent.

BRONCHIAL PROVOCATION TESTS
Airway responsiveness was assessed after the inhalation of two pharmacological agents, methacholine and sodium metabisulphite, and after maximal cardiopulmonary exercise testing. Increasing doubling concentrations of methacholine and sodium metabisulphite, ranging from 1 mg/ml to 6 mg/ml and from 5 mg/ml to 160 mg/ml respectively, with preceding saline solution as baseline were used. Each provocation test was done separately on two different occasions using a nebuliser attached to a dosimeter (model MB3, MEFAR Electomedical, Brescia, Italy; output 0·14 ml per solution). Forced expiratory volume in 1 second (FEV1) was measured 2 minutes after each test with a spirometer (Vitalograph, USA). Doubling concentrations were used every 5 minutes until a ≥ 20% fall in FEV1, from the baseline was noted, or until the maximal concentration for each agent was reached if the fall in FEV1, remained < 20% from baseline. The provocation concentration causing a 20% fall in FEV1, (PC20) was then calculated by linear interpolation. If the fall in FEV1, remained < 20% at a methacholine concentration of 64 mg/ml and a sodium metabisulphite concentration of 160 mg/ml, the PC20 was arbitrarily taken as the next doubling concentration of 128 mg/ml and 320 mg/ml respectively, for the purposes of statistical analysis. Although this may underestimate the PC20 of some patients, such concentrations are high (the PC20 of asthmatic patients is < 8 mg/ml and < 40 mg/ml for methacholine and sodium metabisulphite respectively in our laboratory) and can therefore be regarded as values consistent with a negative provocation test.

CARDIOPULMONARY EXERCISE TESTING
FEV1 was assessed with a spirometer (Vitalograph, USA) before and after maximal treadmill exercise testing on a separate day to examine whether the the airways were hyper-responsive to exercise. Respiratory gas exchange was also analysed during exercise testing to determine peak oxygen consumption as an objective measure of functional capacity. This was done using a respiratory mass spectrometer (Amis 2000, Inovision, Odense, Denmark) by means of the inert gas dilution technique.11 All subjects exercised to exhaustion using the Bruce protocol,12 with the addition of “stage 0” at 1·0 mph and a 5% gradient.

COUGH RESPONSE
The cough response was assessed using low-concentrations of chloride solutions and capsaicin. Four iso-osmolar solutions with decreasing chloride concentrations (150, 75, 37-5, and 0 mM) were used. Inhalations of the solutions were taken for a minute each from an ultrasonic nebuliser (Ultra-Neb 2000, DeVilbiss, Somerset, Pennsylvania, USA)
through the mouth with the subject wearing a noseclip. The number of coughs induced during and 1 minute after nebulisation for each solution was counted by observation. For the capsaicin test, doubling concentrations of capsaicin ranging from 0-975 to 500 μM were used. Single breath inhalations of 0-02 ml solution of each concentration were administered through the mouth from a breath-activated dosimeter (PK Morgan, Gillingham, Kent). The concentration of capsaicin which produced two or more coughs was taken as the threshold concentration. For the purpose of statistical analysis, subjects who had more than two coughs at 500 μM capsaicin were assumed to have a threshold of the next doubling concentration (1000 μM).

### NITRIC OXIDE MEASUREMENT

Exhaled nitric oxide concentration was measured with a modified chemiluminescence analyser (Model LR2000, Logan Research, Rochester, Kent) designed for on-line recording of exhaled nitric oxide and sensitive to concentrations of 2 to 4000 parts per billion (ppb) by volume.¹ Measurements were made by slow exhalation from the mouth for 30–45 seconds from total lung capacity via a wide-bore Teflon tube. Subjects wore a nose-clip and the rate of expiration was kept constant by a visual display of expiratory flow measured by flow sensors in the analyser. The average of two readings measured at end-exhalation were taken. The coefficient of variation (a means of assessing the reproducibility of exhaled nitric oxide concentration) in our laboratory is 7±4%, with most healthy non-smoking individuals having a recording of <20 ppb.

### STATISTICAL ANALYSIS

Paired and unpaired Student’s t tests were used where appropriate to assess the significance of results. Logarithmic transformation of PC20 and of capsaicin concentration causing two or more coughs were used in the analysis of results. For the cough response to low-concentration chloride solutions, median cough counts were used and the significance of results was assessed by the Mann-Whitney U test.

### Results

Patients with chronic heart failure had New York Heart Association class II to IV symptoms (table 1). They had lower peak oxygen consumption than the controls (16-9 (1-3) v 26-5 (2-3) ml/kg/min, P < 0-01) consistent with moderately to severely impaired exercise tolerance. The results of the PC20 for methacholine and sodium metabisulphite are summarised in table 2 with the results of individual heart failure patients and controls given in tables 3 and 4 respectively. The geometric mean PC20 for methacholine was 67-6 (1-3) mg/ml in chronic heart failure and 79-8 (1-3) mg/ml in controls (P = 0-71) and for sodium metabisulphite, 276-7 (1-2) and 290-4 (1-1) mg/ml (P = 0-79) respectively. As noted in tables 3 and 4, the fall in FEV₁ remained < 20% in many subjects at the maximum methacholine and sodium metabisulphite concentrations used in this study (64 mg/ml and 160 mg/ml respectively). To ensure that the mean PC20 obtained for chronic heart failure patients and controls by arbitrarily assuming the PC20 in this subset of subjects to be the next doubling concentration of 128 mg/ml and 320 mg/ml for methacholine and sodium metabisulphite respectively did not lead to a misinterpretation of the results, we also analysed the percentage decrease in FEV₁ from baseline at the provocation concentration of 32 mg/ml for methacholine and at 160 mg/ml for sodium metabisulphite. A methacholine concentration of 32 mg/ml was used.

---

1. DCM, idiopathic dilated cardiomyopathy; IHD, ischaemic heart disease; NYHA, New York Heart Association functional class; LV, left ventricle; PCWP, pulmonary capillary wedge pressure; LVEDP, left ventricular end diastolic pressure; CTR, radiographic cardiothoracic ratio.

2. All patients with a smoking history had stopped smoking for at least 5 years.

3. Pack year = (number of cigarettes smoked per day × number of years smoking) / 20.

---

**Table 1. Clinical characteristics of patients with chronic heart failure**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Cause</th>
<th>NYHA class</th>
<th>Smoking history (pack-years)*</th>
<th>LV ejection fraction (%)</th>
<th>PCWP (mm Hg)</th>
<th>LVEDP (mm Hg)</th>
<th>CTR</th>
<th>Maximum O₂ consumption (ml/kg/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>F</td>
<td>DCM</td>
<td>III</td>
<td>1</td>
<td>12</td>
<td>5</td>
<td>50</td>
<td>13</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>52</td>
<td>F</td>
<td>DCM</td>
<td>III</td>
<td>2</td>
<td>13</td>
<td>12</td>
<td>16</td>
<td>0-5</td>
<td>6-18</td>
</tr>
<tr>
<td>3</td>
<td>66</td>
<td>M</td>
<td>M</td>
<td>III</td>
<td>6</td>
<td>27</td>
<td>12</td>
<td>0-56</td>
<td>6-6</td>
<td>5-6</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>M</td>
<td>M</td>
<td>IV</td>
<td>8</td>
<td>33</td>
<td>Not done</td>
<td>6-13</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>5</td>
<td>46</td>
<td>M</td>
<td>M</td>
<td>II</td>
<td>8</td>
<td>26</td>
<td>19</td>
<td>0-51</td>
<td>17-8</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>47</td>
<td>M</td>
<td>IHD</td>
<td>II</td>
<td>8</td>
<td>26</td>
<td>14</td>
<td>0-50</td>
<td>19-1</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>66</td>
<td>M</td>
<td>IHD</td>
<td>III</td>
<td>16</td>
<td>26</td>
<td>Not done</td>
<td>6-57</td>
<td>24-9</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>68</td>
<td>M</td>
<td>IHD</td>
<td>III</td>
<td>16</td>
<td>26</td>
<td>22</td>
<td>0-58</td>
<td>13-9</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>63</td>
<td>M</td>
<td>DCM</td>
<td>III</td>
<td>16</td>
<td>26</td>
<td>22</td>
<td>0-58</td>
<td>13-9</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>53</td>
<td>M</td>
<td>IHD</td>
<td>III</td>
<td>16</td>
<td>26</td>
<td>27</td>
<td>0-50</td>
<td>13-7</td>
<td></td>
</tr>
</tbody>
</table>

DCM, idiopathic dilated cardiomyopathy; IHD, ischaemic heart disease; NYHA, New York Heart Association functional class; LV, left ventricle; PCWP, pulmonary capillary wedge pressure; LVEDP, left ventricular end diastolic pressure; CTR, radiographic cardiothoracic ratio.

*All patients with a smoking history had stopped smoking for at least 5 years.

---

**Table 2. Summary of results of peak oxygen consumption; radiographic cardiothoracic ratio (CTR); pulmonary function; airway responsiveness to methacholine (MCh); sodium metabisulphite (MBS); and exercise; exhaled nitric oxide concentration; and the cough response to capsaicin and low-concentration chloride solutions in patients with chronic heart failure (CHF) and controls**

| Variable                          | CHF Patients | Controls | p value
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak O₂ consumption (ml/kg/min)</td>
<td>16-9 (1-3)</td>
<td>26-5 (2-3)</td>
<td>&lt; 0-01</td>
</tr>
<tr>
<td>Radiographic CTR</td>
<td>0-56 (0-02)</td>
<td>0-46 (0-01)</td>
<td>&lt; 0-001</td>
</tr>
<tr>
<td>FEV₁ (% predicted)</td>
<td>97-2 (4-5)</td>
<td>110-0 (2-5)</td>
<td>0-03</td>
</tr>
<tr>
<td>PVC (% predicted)</td>
<td>102-2 (5-1)</td>
<td>112-6 (2-9)</td>
<td>NS</td>
</tr>
<tr>
<td>PC20 MCh (mg/ml)</td>
<td>67-6 (1-3)</td>
<td>79-8 (1-3)</td>
<td>NS</td>
</tr>
<tr>
<td>PC20 MBS (mg/ml)</td>
<td>276-7 (1-2)</td>
<td>290-4 (1-1)</td>
<td>NS</td>
</tr>
<tr>
<td>% Change in FEV₁ with exercise</td>
<td>1-44 (0-98)</td>
<td>2-53 (1-1)</td>
<td>NS</td>
</tr>
<tr>
<td>Exhaled nitric oxide (ppb)</td>
<td>12-3 (7-7)</td>
<td>16-2 (3-3)</td>
<td>NS</td>
</tr>
<tr>
<td>Mean capsaicin concentration causing &gt; 2 coughs (μM)</td>
<td>13-5 (2-0)</td>
<td>6-5 (2-1)</td>
<td>NS</td>
</tr>
</tbody>
</table>

**Values**

- peak O₂ consumption (ml/kg/min)
- CTR, cardiothoracic ratio
- FEV₁, forced expiratory volume in 1 second
- PVC, forced vital capacity
- PC20, provocative concentration which caused a 20% drop in FEV₁
- MCh, methacholine
- MBS, metabisulphite

For the purpose of statistical analysis, subjects who had more than two coughs at 500 μM capsaicin were assumed to have a threshold of the next doubling concentration (1000 μM).
because nine of the 10 chronic heart failure patients completed the bronchial provocation test at this concentration compared with only eight at 64 mg/ml. The decrease in FEV₁ was 13-7% v 13-4% (P = 0-97) for metabisulphite and 5-5% v 9-9% (P = 0-2) for sodium metabisulphite in patients with chronic heart failure and in controls respectively, which confirmed that there was no significant difference between the two groups of subjects.

As shown in table 2, the change in FEV₁ after maximal cardiopulmonary exercise testing was +1-44% in chronic heart failure patients and +2-53% in controls (P = 0-47), indicating an absence of exercise-induced bronchospasm in both groups. Exhaled nitric oxide concentration was not increased in the patients with chronic heart failure (12-3 (1-7) v 16-2 (3-3) ppb, P = 0-32).

The results of the cough response to low-concentration chloride solutions and capsaicin are also given in table 2. The median cough counts in chronic heart failure patients were not different from controls for the various low-concentration chloride solutions. The capsaicin concentration causing two or more coughs in chronic heart failure patients was also not significantly different from controls.

Discussion
We were unable to detect any significant airway hyper-responsiveness in patients with stable chronic heart failure in our study. Compared with previous studies, we were more selective in the recruitment criteria in excluding patients with a history of acute pulmonary oedema within six months and of smoking within five years to avoid possible confounding factors. We also assessed airway responsiveness to a wider range of stimuli.

Airway responsiveness is affected not only by bronchial smooth muscle tone but also by the bronchial vascular tone and the activity of autonomic fibres innervating the airways. In view of this, two different pharmacological agents, methacholine and sodium metabisulphite, with different modes of action were chosen to assess airway responsiveness. Methacholine, a commonly used agent and an analogue of acetylcholine, acts directly on airway smooth muscle and is a dilator of bronchial vessels. On the other hand, sodium metabisulphite is a putative stimulant of airway sensory nerves. The observation that patients with chronic heart failure in our study did not show an excessive narrowing of airways with either agent suggests that neither airway smooth muscle hyperresponsive nor its neural activity was upregulated.

Similarly, we were unable to demonstrate airway hyper-reactivity in response to exercise. All the patients were subjected to a maximal treadmill exercise test with a respiratory exchange ratio of >1-1 at peak exercise and all breathed through the mouth which should have accentuated exercise-induced bronchospasm had this been present.

Our findings that airways are not hyper-responsive in stable chronic heart failure parallel those of Eichacker et al. Several subsequent studies have suggested otherwise. There are several possible reasons for the discrepancy. In general, the size of the previous studies in this area was small. Patients with a recent history of acute decompensation and pulmonary congestion were also included in some studies whereas in another, diuretics were stopped before the tests, perhaps inducing airway oedema. Although tests were performed when patients had clinically recovered from the acute event, airways may remain
hyper-responsive as shown by Pison et al. It may be that a reduction in airway hyper-responsiveness lags behind the clinical recovery of pulmonary congestion. Studies on airway function in patients with acute heart failure generally confirm an obstructive airway pattern. This is probably related to peri-bronchial oedema and vascular congestion.

Indeed, Licht and George in a study with a mean follow up of 310 days showed that despite some initial improvement this obstructive pattern persisted for a long time even in non-smokers. How then do acute decompensation and the resultant obstructive airways explain airway hyper-responsiveness? There are several possibilities. It is well known that there is an inverse relation between airway calibre, for which obstructive lung function is an index, and bronchial hyper-responsiveness. The resistance to flow in a tube is inversely proportional to the radius of the tube to the fourth power and thus the effect of spasm on airway narrowing in an already narrowed airway is greatly amplified, even if the tone of smooth muscle contraction is no more than normal. Secondly, narrowed airways facilitate central deposition of aerosol, thus enhancing airway constriction. The additional vasodilatory effects of methacholine on bronchial vessels may also aggravate any peri-bronchial vascular congestion and oedema already present.

Another possible confounding factor is smoking. Smoking leads to different degrees of airway obstruction and as discussed above, an altered baseline lung function will affect bronchial responsiveness on the basis of simple geometric considerations. In addition, smoking may have direct effects on airway responsiveness.

It has been suggested that local inflammation may explain the increased airway responsiveness in some patients. We indirectly assessed this by measuring the exhaled nitric oxide concentration in our patients. Endogenous nitric oxide is synthesised from the amino acid L-arginine by the action of nitric oxide synthase, which has three main isoforms. Constitutive forms of the enzyme are found in endothelial cells which produce nitric oxide (endothelium-derived relaxing factor) responsible for endothelium-dependent vasodilatation, and in neurons, where nitric oxide acts as a neurotransmitter. The other form of the enzyme is the enzyme induced by the action of endotoxin and proinflammatory cytokines in various cell types including leucocytes. Exhaled nitric oxide concentration is increased as a result of inducible enzyme in inflammatory airway diseases such as asthma and bronchiectasis. The finding that exhaled nitric oxide concentration is not increased suggests that local inflammation is not present in patients with stable chronic heart failure. This finding is also compatible with the other results in our study.

The cough response to low-concentration chloride solutions and to capsaicin in patients with chronic heart failure was not significantly different from controls. Afferent fibres of the cough reflex arise in the pulmonary stretch (J) receptors via c fibres; the receptors in the upper airways are of the J type, and the c fibre endings in the mucosa of the larynx, trachea, and bronchi. The c fibres are stimulated by capsaicin and if airway hyper-responsiveness is mediated by the stimulation of J receptors and c fibres by increased pulmonary venous pressures this agent would be expected to enhance the cough reflex. Our finding that the cough response was not different from that in the controls is compatible with the general finding that the airways were not hyper-responsive in our study.

In summary, we were not able to demonstrate any significant airway hyper-responsiveness, either to pharmacological agents or to exercise, in non-smoking patients with stable non-oedematous chronic heart failure receiving, and tolerant to, angiotensin-converting enzyme inhibitors. Exhaled nitric oxide concentration and the cough response were also not enhanced, suggesting that there was no local inflammation or upregulated neural mechanisms. It is therefore unlikely that airway hyper-responsiveness contributes significantly to the exertional dyspnoea seen in chronic heart failure patients in a stable condition. However, our findings do not exclude the presence of airway hyper-responsiveness in patients with acute pulmonary oedema or during the recovery period.

**LIMITATIONS OF THE STUDY**

Because of the selective recruitment criteria, the number of patients in this study was small and may have limited the study. Another potential limitation is that all the patients with chronic heart failure were receiving angiotensin-enzyme inhibitors which may have altered airway responsiveness and the cough reflex. We chose a control group of asymptomatic hypertensive patients also taking angiotensin-converting enzyme inhibitors to circumvent this confounding factor. In any case, no subjects had a history of intolerance of the medication or of developing a cough during treatment. Had angiotensin-converting enzyme inhibitors affected the results, an abnormal cough response and an increased airway responsiveness should have been present but neither was seen. In an earlier study patients who coughed during treatment with angiotensin-converting enzyme inhibitors also had bronchial hyper-reactivity when they were not receiving the treatment. It is thus possible that the patients in our study had already been “pre-selected” by virtue of their tolerance to angiotensin converting enzyme inhibitors—that is, patients intolerant of this class of drug may indeed have latent bronchial hyper-responsiveness despite the absence of a history of asthma or asthmatic symptoms, such variation has been recognised in other studies. The development of airway hyper-responsiveness may thus be complex and multifactorial in origin, depending on genetic characteristics, pathophysiological mechanisms, and environmental factors (such as smoking, pollution and concomitant respiratory tract infection).
Airway responsiveness and exhaled nitric oxide in non-smoking patients with stable chronic heart failure

TPC is supported by a junior research fellowship from the British Heart Foundation. AJSC is supported by the Vincent Royston Trust and British Heart Foundation.